CAMBRIDGE and NEWCASTLE, UK, 03 June 2024: DefiniGEN Ltd., and Atelerix Ltd., today announced they have successfully shipped in vitro liver models from the UK to a top tier pharma customer in the US. The agreement between the companies combines DefiniGEN’s mechanistically relevant iPSC hepatocytes (Opti-Heps) with Atelerix's hydrogel preservation technology, which prevents loss of function and enables even sensitive samples to remain stable at ambient temperatures for up to two weeks.
News
The Femtech & Women’s Health edition of ‘Discovery Spark’ champions early stage businesses working to close the gender health gap
Sandwich, Kent, UK / 30th May 2024 / Discovery Park, Kent’s thriving life science and innovation community, announced the selection of 11 promising start-ups in FemTech & Women’s Health to join Discovery Spark, their growth and support programme for early stage businesses.
Three-storey, multi-occupancy building on track to provide fully fitted laboratory suites for fast-growing life science community within the Cambridge cluster
Bruntwood SciTech is announcing the launch of its new Life Science Accelerator programme at Alderley Park in a move aimed at supporting even greater innovation and economic growth in the region.
Cambridge, 30th May 2024: Six life science start-ups looking to develop products and services to make a positive difference to healthcare have been selected for one of Europe’s top incubators based at the Babraham Research Campus in Cambridge – Accelerate@Babraham.
Tokyo, Japan, Oxford and Cambridge, UK, 30 May 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) and PrecisionLife, the Causal AI precision medicine company, today announce the expansion of their strategic R&D partnership into auto-immune disorders with the potential to identify new drug targets for the treatment of complex, chronic conditions.
RNA sequencing is becoming the gold-standard method for uncovering the cellular mechanisms behind disease. A variety of RNA sequencing techniques have evolved, which provide all-important information on disease causes and progression for more effective treatments.
Read our latest blog here:
https://sourcebioscience.com/comparing-rna-sequencing-techniques/
Source LDPath is a flexible and trusted extension to your histopathology laboratory, supporting you to accelerate turnaround times for reporting and decrease backlogs.
In 2023, we successfully reported over 260,000 cases with our NHS histopathology partners, and we are delighted to announce that we have further increased our capacity this year to support your department and provide better patient care.
We have capacity to support:
We are delighted to announce that our latest whitepaper, written in collaboration with Deloitte: 'Australian R&D Cashback and Early Development Activities', is now available to read and download.